Innovent Biologics : China's NMPA Approves Limertinib For The First-line Treatment Of Lung Cancer
26/4 06:06
(RTTNews) - Innovent Biologics Inc. announced that China's National Medical Products Administration or NMPA has approved the New Drug Application (NDA) for limertinib as the first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NS...